Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...
A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big ...
People visit the booth of Johnson & Johnson at the China International Import Expo (CIIE) in Shanghai, China November 7, 2024. REUTERS/Andrew Silver/File Photo Johnson & Johnson said on Monday it ...
Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback